论文部分内容阅读
目的ＩＬ－２基因修饰人骨肉瘤细胞的制备及骨肉瘤患者ＩＬ－２、ｓＩＬ－２Ｒ水平测定。方法用逆转录病毒载体将人ＩＬ－２基因插入人骨肉瘤细胞系制备成ＩＬ－２基因修饰骨肉瘤细胞；用放射免疫法及ＥＬＩＳＡ法检测骨肉瘤患者血清内ＩＬ－２、ｓＩＬ－２Ｒ水平。结果经Ｇ４１８筛选和ＰＣＲ鉴定后制备成功人骨肉瘤ＩＬ－２基因修饰细胞，并证实其有分泌ＩＬ－２功能，用ＭＴＴ法测得其培养上清中ＩＬ－２表达量为每１ｘ１０５细胞２４小时５０－８００ｕ。骨肉瘤患者免疫功能调查发现其血清ＩＬ－２水平明显低于正常，而ｓＩＬ－２Ｒ则明显高于正常，术后两者可逐渐正常。结论 制备成功ＩＬ－２基因修饰骨肉瘤细胞并发现骨肉瘤患者ＩＬ－２水平低下，为进行骨肉瘤基因治疗创造条件。
Preparation of IL-2 gene-modified human osteosarcoma cells and determination of IL-2 and sIL-2R in osteosarcoma patients. METHODS: IL-2 gene-modified osteosarcoma cells were prepared by inserting human IL-2 gene into human osteosarcoma cell line with retroviral vectors. Serum levels of IL-2 and sIL-2R in osteosarcoma patients were detected by radioimmunoassay and ELISA. Results The IL-2 gene-modified cells of human osteosarcoma were successfully prepared after G418 selection and PCR identification, and IL-2 function was confirmed. The expression level of IL-2 in culture supernatant was 24 hours per 1×10 5 cells by MTT assay. 50-800u. The investigation of immune function of osteosarcoma patients found that serum IL-2 levels were significantly lower than normal, while sIL-2R was significantly higher than normal, and the two can be gradually normal after surgery. Conclusion The IL-2 gene modified osteosarcoma cells were successfully prepared and the IL-2 level in osteosarcoma patients was low, which provided the conditions for the gene therapy of osteosarcoma.